Good to see the cardiologists (looking at you @AhmedAlkaisey) putting SGLT2i front and centre in the latest heart failure guidelines! The flood of SGLT2i use spreads on. #diabetes #medtwitter #endotwitter https://t.co/qPCaUuOsoX
RT @JJheart_doc: @ChristosArgyrop YES. I'll give the #cardiology corollary: #protip if you are doing #cardiology clinic and you see a patie…
@ChristosArgyrop YES. I'll give the #cardiology corollary: #protip if you are doing #cardiology clinic and you see a patient who should be on an #SGLT2i or #GLP-1RA but is not (and there is no good explanation for why not)--start them on an SGLT2i or GLP1-
RT @hillypaige2: #HID2021 Impressive presentation by Melissa Magwire, the director of the CardioMetabolic Center Alliance on the @ACCinTouc…
RT @hillypaige2: #HID2021 Impressive presentation by Melissa Magwire, the director of the CardioMetabolic Center Alliance on the @ACCinTouc…
RT @hillypaige2: #HID2021 Impressive presentation by Melissa Magwire, the director of the CardioMetabolic Center Alliance on the @ACCinTouc…
RT @hillypaige2: #HID2021 Impressive presentation by Melissa Magwire, the director of the CardioMetabolic Center Alliance on the @ACCinTouc…
#HID2021 Impressive presentation by Melissa Magwire, the director of the CardioMetabolic Center Alliance on the @ACCinTouch ECD on #CVD reduction in #diabetes ➡️https://t.co/ZgLOUCvRXt ✅ @cardiometalli experience is so encouraging! #ClinicalInertia @hearti
@RamkiSitaraman @sumanthraman The most important things you can do are control BP, DM, exercise, eat a healthful diet, maintain a healthy weight. There are newer medications -- expensive...of course -- that are promising for reducing progression: SGLT2i
Flashback Friday: 2020 Expert Consensus on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. #SGLT2i #GLP1 Read more: https://t.co/7tCd0DMioq
RT @DavidACohen_MD: First major organization to recommend an GLP-1 agonist or SGLT2 Inhibitor as first line treatment over metformin for ma…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @Beska: @DrLindaDykes @diet_cokeaddict @atomicallyblond @graeme1spencer @clara_neuro @piugreen Flozins are licensed now for symptomatic…
@DrLindaDykes @diet_cokeaddict @atomicallyblond @graeme1spencer @clara_neuro @piugreen Flozins are licensed now for symptomatic HF without diabetes in Europe. NICE haven’t spoken up yet. JACC consensus recently strongly supports flozins in those with T2DM
Novel therapies for CV risk reduction on #diabetes @JACCJournals #KidneyWk https://t.co/5NNyrc1Gjq
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/Jng6ZbcJ05
@MaioranaCarlos @ESC_Journals @alavallecobo @SAC_54 @SIAC_cardio @SACJoven @SACcardiometab1 @edurontoFF @clara_clarais @paomorejon @ValleAlfonso @ezeforte @rafavidalperez @jpcostabel Gracias Carlos. En pacientes de alto riesgo o con enf. CV, el consenso AC
RT @DavidACohen_MD: First major organization to recommend an GLP-1 agonist or SGLT2 Inhibitor as first line treatment over metformin for ma…
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/FaNHxoNTvD
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes @UCSFCardiology @UCSFIMChiefs @UCSFMedicine @UCSFFCMRP @UCSF_CVfellows @WUSTLmed @OHSUCardFellow
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
RT @JJheart_doc: @heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--a…
#heartfailurechat @JJheart_doc @CardiologyToday @IntegrityCE
@khurramn1 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien @kershawpatel @MichaelJBlaha @HMHCardioFellow Check the @ACCinTouch consensus on this topic! I use #GLP1 antagonists in my patients that are more atherothrombo
@heartdoc73 @DrMarthaGulati @CardiologyToday @IntegrityCE @GiuseppeGalati_ @hvanspall @DrNasrien It's been a great ride--all cardiologists should get aboard! The @ACCinTouch consensus doc is great reading. https://t.co/4cNUT9hCa0
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/FaNHxoNTvD
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
Consenso sobre antidiabéticos SGLT2 y AGLP1 para disminuir el riesgo cardiovascular By @JACCJournals Recomendaciones para optimizar el inicio del Tto y la individualización en pacientes con DM2. https://t.co/vTTgrO8rSb #diabetes https://t.co/qSmpG8M6VJ
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN https://t.co/3yoIwmeTfE
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
@cindyluzy Great Article 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. https://t.co/OGq71ux6Rt
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/mbHlbeiMV8
Dos documentos de expertos (@ACCinTouch y @escardio) destacan la importancia de los nuevos antidiabéticos en la reducción del riesgo cardiovascular en la Insuficiencia Cardiaca 👉🏻https://t.co/E3GzfJR2vi 👉🏻https://t.co/qVWKeo9es0
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2FPTIY
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/xPqM2Fyiko
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @tripdatabase: New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/FaNHxoNTvD
New2Trip: Novel Therapies for Cardiovascular Risk Reduction in Patients w/ Type 2 Diabetes https://t.co/FaNHxoNTvD
RT @tufarmaceuTIC: DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos c…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @tufarmaceuTIC: DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos c…
RT @tufarmaceuTIC: DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos c…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @tufarmaceuTIC: DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos c…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @SEHLELHA140_90: 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Dia…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @tufarmaceuTIC: DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos c…
DM2 y ECV: Inhibidores de SGLT2 y Agonistas del GLP-1 se posicionan como terapias de elección. Ojo a efectos adversos como infecciones del tracto urinario y tejidos blandos en iSGLT2 y efectos gastrointestinales / pancreatitis en GLP-1RAs. https://t.co/H
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes https://t.co/FgBlXnuThH
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @BITNavarra: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes vía @sociedadSEEN
RT @jlgorriz: Articulo de obligada lectura: 2020 Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients Wit…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…
RT @sociedadSEEN: Nueva guía del ACC sobre la reducción del riesgo de ECV en diabetes *La #ECV sigue siendo la principal causa de morbi y m…